Viewing Study NCT06657157

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:35 PM
Ignite Modification Date: 2026-05-26 @ 12:48 PM
Study NCT ID: NCT06657157
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2024-10-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma
Sponsor: Comprehensive Cancer Center Munich (CCCM)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Urothelial Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None enfortumab vedotin View
None Pembrolizumab View
None peripheral neuropathy View
None metastatic urothelial carcinoma View
None advanced urothelial carcinoma View